Deerfield Management Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
64
- Investments
-
325
- Portfolio
-
113
- Exits
-
177
Deerfield Management General Information
Description
Founded in 1994, Deerfield Management is a venture capital firm based in New York, New York. The firm seeks to invest in the healthcare, pharmaceutical, biotechnology, healthcare devices, diagnostic, digital health, supplies, healthcare services, life sciences, and oncology sectors.
Contact Information
Website
www.deerfield.com
Year Founded
1994
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Hedge Fund
Primary Office
- 345 Park Avenue South
- New York, NY 10010
- United States
+1 (212) 000-0000
Deerfield Management Investments (325)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Perceive Bio | 28-Dec-2022 | Later Stage VC | 0000 | Drug Discovery | Generating Revenue | 0000000 0000000 00.0 |
| 000000000 | 17-Nov-2022 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
| 0000 00000000 | 08-Nov-2022 | 0000 | 000.00 | Drug Delivery | Generating Revenue | |
| 000000 00000000000 | 03-Nov-2022 | 0000 | 0000 | Drug Discovery | Generating Revenue/Not Profitable | |
| 00000 0000 | 02-Nov-2022 | 00000 00000 | 000.00 | Outcome Management (Healthcare) | Generating Revenue | 000000 000000 00 |
| 0000 | 17-Oct-2022 | 00 000000000 | Outcome Management (Healthcare) | Generating Revenue | ||
| 000000000000000 00 | 13-Sep-2022 | 0000000000 | Other Devices and Supplies | Generating Revenue | ||
| 00000000000 000000 | 09-Sep-2022 | 0000 | 00000 | Drug Discovery | Generating Revenue | |
| Vigil Neuro | 16-Aug-2022 | PIPE | 0000 | Drug Discovery | Generating Revenue | |
| Innervace | 08-Aug-2022 | Early Stage VC | 0000 | Biotechnology | Pre-Clinical Trials | 00000 000000000 00.0 |
Deerfield Management Exits (177)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Graybug Vision | 22-Nov-2022 | Merger/Acquisition | |
| 000 00000000000000 | 08-Nov-2022 | 0000000 000000 | 00000 |
| 00000 000000 | 30-Sep-2022 | 000000000000000000 | |
| 000000 | 06-May-2022 | 000 | 00000 |
| 00000000 | 29-Apr-2022 | 000 | 00000 |
| 000000 00000000000 | 28-Apr-2022 | 000000 0000000000 | 00000 |
| 00000 000000000000 | 22-Oct-2021 | 000 | 00000 |
| 000000000 | 20-Oct-2021 | 000000000000000000 | 00000 |
| Headspace | 15-Oct-2021 | Merger of Equals | |
| Farapulse | 06-Aug-2021 | Merger/Acquisition | 00000 |
Deerfield Management Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Deerfield Management Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Deerfield Management Team (98)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Jonathan Isler | Chief Financial Officer & Partner | New York, NY | |||
| Alexis Cazé | Partner & Chief Operating Officer | New York, NY | |||
| Jana Jensen Ph.D | Chief Operating Officer, Deerfield Discovery and Development | 0 | New York, NY | ||
| Angelo Stornello | Chief Technology Officer | New York, NY | |||
| James Flynn | Managing Partner | 00 | 0 | 0 | New York, NY |
Deerfield Management Co-Investors (376)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| RA Capital Management | 16 | 0 | 00 |
|
|
| Cormorant Asset Management | 00 | 0 |
|
|
|
| OrbiMed | 00 | 0 | 0 |
|
|
| Logos Capital | 0 | 0 |
|
|
|
| Perceptive Advisors | 0 | 0 | 0 |
|
|